2025
Gross tumor volume confidence maps prediction for soft tissue sarcomas from multi-modality medical images using a diffusion model
Dong Y, Marin T, Zhuo Y, Najem E, Moteabbed M, Xing F, Beddok A, Lahoud R, Rozenblum L, Ding Z, Liu X, Grogg K, Woo J, Chen Y, Lim R, Ma C, Fakhri G. Gross tumor volume confidence maps prediction for soft tissue sarcomas from multi-modality medical images using a diffusion model. Physics And Imaging In Radiation Oncology 2025, 33: 100734. PMID: 40123775, PMCID: PMC11926426, DOI: 10.1016/j.phro.2025.100734.Peer-Reviewed Original ResearchGross tumor volumeSoft tissue sarcomasTissue sarcomasGross tumor volume delineationManual GTV delineationsMagnetic resonance imagingComputed tomographyFluorodeoxyglucose positron emission tomographyGTV delineationT1-weighted magnetic resonance imagingSingle-modePositron emission tomographyMulti-modal medical imagesTumor volumeIntra-reader variabilityFDG-PETTreatment planningSarcomaEmission tomographyImaging modalitiesResonance imagingDiffusion modelDice indexReader variabilityPatients
2024
Hearing Preservation and Functional Outcomes After Resection of Epidermoid Lesions of the Cerebellopontine Angle With High Hearing Risk
Papazian M, Cottrell J, Yang J, Kay-Rivest E, Friedmann D, Jethanamest D, Kondziolka D, Pacione D, Sen C, Golfinos J, Roland J, McMenomey S. Hearing Preservation and Functional Outcomes After Resection of Epidermoid Lesions of the Cerebellopontine Angle With High Hearing Risk. Otology & Neurotology 2024, 46: 308-313. PMID: 39951666, DOI: 10.1097/mao.0000000000004408.Peer-Reviewed Original ResearchConceptsInternal auditory canalCerebellopontine anglePostoperative audiogramsPreoperative hearingHearing preservationAssociated with hearing outcomesEpidermoid lesionsInternal auditory canal involvementExperience of treating patientsHearing preservation rateGross total resectionAverage tumor volumeHEAR scoreHearing riskHearing lossCerebellopontine angle epidermoidsHearingOutcome measuresEvidence of lesionsMicrosurgical resectionTotal resectionPreoperative extentStatistically significant changesTumor volumeAuditory canalComparing the Accuracy and Reliability of ABC/2 and Planimetry for Vestibular Schwannoma Volume Assessment
Singh K, Abdou H, Panth N, Chiang V, Buono F, Schwartz N, Mahajan A. Comparing the Accuracy and Reliability of ABC/2 and Planimetry for Vestibular Schwannoma Volume Assessment. Otology & Neurotology 2024, 46: 196-200. PMID: 39792983, DOI: 10.1097/mao.0000000000004392.Peer-Reviewed Original ResearchConceptsTumor volume assessmentABC/2 methodVestibular schwannomaVolume assessmentPlanimetry methodTumor volumeTumor volume changesFollow-up scansOverestimate tumor volumePatients' quality of lifeTumor sizeRetrospective reviewIntracranial tumorsImprove clinical decision makingSubgroup analysisVolumetric assessmentTumorClinical decision makingQuality of lifePatients' qualityPatientsClinical settingPlanimetryImaging techniquesPositive correlationRADT-12. DERIVING IMAGING BIOMARKERS FOR PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA USING DEEP LEARNING
Zhu J, Hager T, Chadha S, Sritharan D, Weiss D, Hossain S, Osenberg K, Moore N, Aneja S. RADT-12. DERIVING IMAGING BIOMARKERS FOR PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA USING DEEP LEARNING. Neuro-Oncology 2024, 26: viii74-viii74. PMCID: PMC11553274, DOI: 10.1093/neuonc/noae165.0296.Peer-Reviewed Original ResearchPrimary central nervous system lymphomaWhole-brain radiotherapyTreated with chemotherapyOverall survivalHigh-risk groupPatient phenotypesCentral nervous system lymphomaPCNSL treatmentRisk of neurocognitive side effectsImaging biomarkersC-statisticOne-year OSTwo-year OSNervous system lymphomaAssociated with improved outcomesLog-rank testNeurocognitive side effectsTime-dependent AUCBrain radiotherapySystem lymphomaTumor volumeTumor sizeRisk stratificationAnalyses assessed differencesSub-analysisGrowth differentiation factor 15 (GDF15) predicts relapse free and overall survival in unresected locally advanced non-small cell lung cancer treated with chemoradiotherapy
Di Pastena F, Pond G, Tsakiridis E, Gouveia A, Ahmadi E, Biziotis O, Ali A, Swaminath A, Okawara G, Ellis P, Abdulkarim B, Ahmed N, Robinson A, Roa W, Valdes M, Kavsak P, Wierzbicki M, Wright J, Steinberg G, Tsakiridis T. Growth differentiation factor 15 (GDF15) predicts relapse free and overall survival in unresected locally advanced non-small cell lung cancer treated with chemoradiotherapy. Radiation Oncology 2024, 19: 155. PMID: 39511611, PMCID: PMC11542377, DOI: 10.1186/s13014-024-02546-y.Peer-Reviewed Original ResearchConceptsLocally advanced non-small cell lung cancerAdvanced non-small cell lung cancerNon-small cell lung cancerCell lung cancerOverall survivalDifferentiation factor 15GDF15 levelsLA-NSCLCTumor volumeSurvival outcomesUnresectable locally advanced non-small cell lung cancerLung cancerPhase II randomized clinical trialConcurrent chest radiotherapyIncreased GDF15 levelsUnresectable LA-NSCLCTreated with chemoradiotherapyGross target volumeGrowth differentiation factor 15Platinum-based chemotherapyPlasma GDF15 levelsRandomized to treatmentLevels of GDF15Patient blood plasmaRandomized clinical trialsG9a/DNMT1 co-targeting inhibits non-small cell lung cancer growth and reprograms tumor cells to respond to cancer-drugs through SCARA5 and AOX1
Exposito F, Redrado M, Serrano D, Calabuig-Fariñas S, Bao-Caamano A, Gallach S, Jantus-Lewintre E, Diaz-Lagares A, Rodriguez-Casanova A, Sandoval J, San Jose-Eneriz E, Garcia J, Redin E, Senent Y, Leon S, Pio R, Lopez R, Oyarzabal J, Pineda-Lucena A, Agirre X, Montuenga L, Prosper F, Calvo A. G9a/DNMT1 co-targeting inhibits non-small cell lung cancer growth and reprograms tumor cells to respond to cancer-drugs through SCARA5 and AOX1. Cell Death & Disease 2024, 15: 787. PMID: 39488528, PMCID: PMC11531574, DOI: 10.1038/s41419-024-07156-w.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerNon-small cell lung cancer patientsCM-272Treatment of non-small cell lung cancerReprogram tumor cellsAssociated with poor prognosisResponse to chemotherapyCell lung cancerCancer drugsMonitor tumor progressionOverexpression of G9aNSCLC cell linesLung cancer growthCancer drug sensitivityNon-small cell lung cancer growthNon-invasive biomarkersTumor volumeAntitumor efficacyTargeted therapyPoor prognosisCancer modelsTumor cellsInduce cell deathTumor progressionLung cancerImpact of Synthetic PET Evaluation prior to PET-Guided Functional Modeling in Optimizing Patient Selection for Biology-Guided Radiotherapy
Hicks D, Chen H, Kim J, Tressel L, Wallington D, Becht K, Johung K, Young M, Feghali K, de Jong D, Chen Z, Carlson D, Park H. Impact of Synthetic PET Evaluation prior to PET-Guided Functional Modeling in Optimizing Patient Selection for Biology-Guided Radiotherapy. International Journal Of Radiation Oncology • Biology • Physics 2024, 120: s162-s163. DOI: 10.1016/j.ijrobp.2024.07.2188.Peer-Reviewed Original ResearchPlanning target volumeInternal target volumeBiology-guided radiotherapyStereotactic body radiotherapyGross tumor volumeTarget volumeCT simulationOptimal patient selectionPET evaluationStereotactic body radiotherapy planLung target volumesPatient selectionPTV edgesLung casesBgRTPET-CTTumor sizeTumor volumeRadiotherapyCase 2PET dataLungActivity concentrationsPatientsConsistent with resultsUse of Mitotic Activity and the Size of Any Dedifferentiated Component for Risk Assessment in MDM2-Amplified Liposarcoma.
Wu H, Sukhanova M, Tang H, Lu X, Zhong M, Deshpande H, Pollack S, Laskin W, Alexiev B. Use of Mitotic Activity and the Size of Any Dedifferentiated Component for Risk Assessment in MDM2-Amplified Liposarcoma. Archives Of Pathology & Laboratory Medicine 2024 PMID: 39164013, DOI: 10.5858/arpa.2024-0098-oa.Peer-Reviewed Original ResearchAtypical lipomatous tumor/well-differentiated liposarcomaMDM2-amplified liposarcomasDedifferentiated componentDedifferentiated liposarcomaAdverse eventsMitotic countLocal recurrence statusMDM2 copy numberAssociated with adverse eventsLog-rank testOverall tumor volumeUnivariate logistic regressionChromosome 12q13-15Statistically significant associationPercentage of cellsTumor dimensionTumor volumeTumor sizeMDM2 proto-oncogeneClinicopathological characteristicsPathology reportsGrade 3Recurrence statusUnivariate analysisMultivariate regression modelDisulfiram/copper complex improves the effectiveness of the WEE1 inhibitor Adavosertib in p53 deficient non-small cell lung cancer via ferroptosis
Liu D, Cao J, Ding X, Xu W, Yao X, Dai M, Tai Q, Shi M, Fei K, Xu Y, Su B. Disulfiram/copper complex improves the effectiveness of the WEE1 inhibitor Adavosertib in p53 deficient non-small cell lung cancer via ferroptosis. Biochimica Et Biophysica Acta (BBA) - Molecular Basis Of Disease 2024, 1870: 167455. PMID: 39111630, DOI: 10.1016/j.bbadis.2024.167455.Peer-Reviewed Original ResearchWEE1 inhibitorNon-small cell lung cancerNSCLC cellsCell lung cancerSynergistic therapeutic approachesProtein levelsEffective treatment strategiesPro-oxidant drugsKinase activity of Wee1P53-deficient cellsActivity of Wee1Tumor volumeCombination therapyDSF-CuRepurposing disulfiramTumor weightSolute carrier family 7 memberWee1 protein levelsP53 deficiencyPoor prognosisReduced cell viabilityFunctional p53Lung cancerTreatment strategiesXenograft modelVascular mimicry as a facilitator of melanoma brain metastasis
Provance O, Oria V, Tran T, Caulfield J, Zito C, Aguirre-Ducler A, Schalper K, Kluger H, Jilaveanu L. Vascular mimicry as a facilitator of melanoma brain metastasis. Cellular And Molecular Life Sciences 2024, 81: 188. PMID: 38635031, PMCID: PMC11026261, DOI: 10.1007/s00018-024-05217-z.Peer-Reviewed Original ResearchConceptsVascular mimicryBrain metastasesMouse model of metastatic melanomaIncreased risk of metastasisAssociated with tumor volumeMelanoma brain metastasesRisk of metastasisSurvival of miceFuture treatment regimensCell line modelsTumor suppressor pathwayMetastatic melanomaTumor volumeSolid tumorsTreatment regimensTumor typesPoor prognosisHippo tumor suppressor pathwayIncreased riskMouse modelDownstream targets YAPMelanomaMetastasisSuppressor pathwayTumorThe role of 18F-FDG PET in minimizing variability in gross tumor volume delineation of soft tissue sarcomas
Najem E, Marin T, Zhuo Y, Lahoud R, Tian F, Beddok A, Rozenblum L, Xing F, Moteabbed M, Lim R, Liu X, Woo J, Lostetter S, Lamane A, Chen Y, Ma C, El Fakhri G. The role of 18F-FDG PET in minimizing variability in gross tumor volume delineation of soft tissue sarcomas. Radiotherapy And Oncology 2024, 194: 110186. PMID: 38412906, PMCID: PMC11042980, DOI: 10.1016/j.radonc.2024.110186.Peer-Reviewed Original ResearchGross tumor volume delineationGross tumor volumeDice similarity coefficientF-FDG PET imagingSoft tissue sarcomasInter-reader variabilityGTV delineationRadiation therapy treatment planningF-FDGF-FDG PETTherapy treatment planningPerformance level estimationTumor volume delineationTissue sarcomasPET imagingVolume delineationSimultaneous truthHausdorff distanceDice similarity coefficient scoreAccurate gross tumor volumeImaging modality groupsWilcoxon signed-rank testStatistically significant decreaseSigned-rank testTumor volume
2023
Recommendations for assessing appearance concerns related to plexiform and cutaneous neurofibromas in neurofibromatosis 1 clinical trials
Merker V, Thompson H, Wolters P, Buono F, Hingtgen C, Rosser T, Barton B, Barnett C, Smith T, Haberkamp D, McManus M, Baldwin A, Moss I, Röhl C, Martin S. Recommendations for assessing appearance concerns related to plexiform and cutaneous neurofibromas in neurofibromatosis 1 clinical trials. Clinical Trials 2023, 21: 6-17. PMID: 38140900, PMCID: PMC10922038, DOI: 10.1177/17407745231205577.Peer-Reviewed Original ResearchPatient-reported outcome measuresClinical trialsOutcome measuresNeurofibromatosis 1Cutaneous neurofibromasDistress ScaleOlder adultsFinal consensus recommendationsKey secondary outcomesPatient-reported outcomesPatient-reported changesAppearance concernsSystematic literature searchNontumor manifestationsTreatment sequelaeSecondary outcomesBACKGROUND/Consensus recommendationsPatient's perspectiveTumor volumePatient representativesGood psychometric propertiesOutcome ratingsLiterature searchPlexiformNodal tumor volume as a prognostic factor for oral squamous cell carcinoma—a systematic review
Bernasconi M, Bilic A, Kauke-Navarro M, Safi A. Nodal tumor volume as a prognostic factor for oral squamous cell carcinoma—a systematic review. Frontiers In Oral Health 2023, 4: 1229931. PMID: 37654649, PMCID: PMC10467257, DOI: 10.3389/froh.2023.1229931.Peer-Reviewed Original ResearchOral squamous cell carcinomaNodal tumor volumeSquamous cell carcinomaPrognostic factorsPrognostic significanceCell carcinomaTumor volumeSystematic reviewAccurate nodal stagingLymph node metastasisNodal disease burdenNovel prognostic factorPoor survival outcomesPoor survival rateTraditional staging methodsNode metastasisSurvival outcomesNodal stagingDisease burdenInclusion criteriaPrognostic assessmentOSCC managementElectronic databasesSurvival rateMajority of studiesCyberKnife Stereotactic Radiosurgery for Growing Vestibular Schwannoma: Longitudinal Tumor Control, Hearing Outcomes, and Predicting Post‐Treatment Hearing Status
Hildrew D, Perez P, Mady L, Li J, Nilsen M, Hirsch B. CyberKnife Stereotactic Radiosurgery for Growing Vestibular Schwannoma: Longitudinal Tumor Control, Hearing Outcomes, and Predicting Post‐Treatment Hearing Status. The Laryngoscope 2023, 134: s1-s12. PMID: 37178050, DOI: 10.1002/lary.30731.Peer-Reviewed Original ResearchConceptsTumor control rateCyberKnife stereotactic radiosurgeryHearing outcomesVestibular schwannomaControl rateStereotactic radiosurgeryRetrospective case series reviewCase series reviewThird of patientsProportional hazard modelingMaximum radiation doseSeries reviewTumor controlAvailable audiogramsOtolaryngology-HeadTumor volumeEffective treatmentClass APatientsHearing statusAmerican AcademyHazard modelingVolumetric analysisRadiation doseOutcomes
2022
NS-HGlio: A generalizable and repeatable HGG segmentation and volumetric measurement AI algorithm for the longitudinal MRI assessment to inform RANO in trials and clinics
Abayazeed A, Abbassy A, Müeller M, Hill M, Qayati M, Mohamed S, Mekhaimar M, Raymond C, Dubey P, Nael K, Rohatgi S, Kapare V, Kulkarni A, Shiang T, Kumar A, Andratschke N, Willmann J, Brawanski A, De Jesus R, Tuna I, Fung S, Landolfi J, Ellingson B, Reyes M. NS-HGlio: A generalizable and repeatable HGG segmentation and volumetric measurement AI algorithm for the longitudinal MRI assessment to inform RANO in trials and clinics. Neuro-Oncology Advances 2022, 5: vdac184. PMID: 36685009, PMCID: PMC9850874, DOI: 10.1093/noajnl/vdac184.Peer-Reviewed Original ResearchHigh-grade gliomasNeuro-Oncology criteriaResidual tumor volumeTreatment response monitoringIntraclass correlation coefficientMRI assessmentTreatment responseTumor volumeResponse assessmentRadiation planningTumor tissueInternal validationResponse monitoringGBM datasetsMRIExternal validationVolumetric measurementsEDDice similarity coefficientA tumor volume and performance status model to predict outcome prior to treatment in diffuse large B-cell lymphoma
Thieblemont C, Chartier L, Dührsen U, Vitolo U, Barrington S, Zaucha J, Vercellino L, da Silva M, Patrocinio-Carvalho I, Decazes P, Viailly P, Tilly H, Berriolo-Riedinger A, Casasnovas O, Hüttmann A, Ilyas H, Mikhaeel N, Dunn J, Cottereau A, Schmitz C, Kostakoglu L, Paulson J, Nielsen T, Meignan M. A tumor volume and performance status model to predict outcome prior to treatment in diffuse large B-cell lymphoma. Blood Advances 2022, 6: 5995-6004. PMID: 36044385, PMCID: PMC9691911, DOI: 10.1182/bloodadvances.2021006923.Peer-Reviewed Original ResearchConceptsLarge B-cell lymphomaAggressive large B-cell lymphomaB-cell lymphomaRisk factorsTumor volumePerformance statusDiffuse large B-cell lymphomaInternational Prognostic IndexMetabolic tumor volumeProgression-free survivalReal-world seriesReal-world clinicsREMARC trialOverall survivalRefractory diseaseECOG-PSPrognostic indexIntermediate riskInitial treatmentTreatment initiationRisk stratificationC-indexOlder patientsPrognostic toolClinical trialsFull automation of total metabolic tumor volume from FDG-PET/CT in DLBCL for baseline risk assessments
Jemaa S, Paulson J, Hutchings M, Kostakoglu L, Trotman J, Tracy S, de Crespigny A, Carano R, El-Galaly T, Nielsen T, Bengtsson T. Full automation of total metabolic tumor volume from FDG-PET/CT in DLBCL for baseline risk assessments. Cancer Imaging 2022, 22: 39. PMID: 35962459, PMCID: PMC9373298, DOI: 10.1186/s40644-022-00476-0.Peer-Reviewed Original ResearchConceptsDiffuse large B-cell lymphomaProgression-free survivalOverall survivalFDG-PETUntreated diffuse large B-cell lymphomaHazard ratioHigh-risk DLBCL patientsCentral nervous system relapseLarge B-cell lymphomaMetabolic tumor volumeImaging-based risk factorsB-cell lymphomaEnhanced risk stratificationHigh-risk populationImaging metricsRisk increaseDLBCL patientsFDG-PET/CTSystemic relapseTumor volumeOrgan involvementPrognostic improvementRisk stratificationInvasive proceduresClinical dataFeasibility study of clinical target volume definition for soft-tissue sarcoma using muscle fiber orientations derived from diffusion tensor imaging
Shusharina N, Liu X, Coll-Font J, Foster A, Fakhri G, Woo J, Bortfeld T, Nguyen C. Feasibility study of clinical target volume definition for soft-tissue sarcoma using muscle fiber orientations derived from diffusion tensor imaging. Physics In Medicine And Biology 2022, 67: 155013. PMID: 35817048, PMCID: PMC9344976, DOI: 10.1088/1361-6560/ac8045.Peer-Reviewed Original ResearchConceptsClinical target volumeSoft tissue sarcomasHealthy volunteersClinical target volume definitionClinical target volume delineationRight thighGross tumor volumeTarget volume definitionEcho-planar acquisitionsTarget volumeAuto-segmentationTumor volumeVolume definitionSarcoma patientsTissue sarcomasCT planeConvolutional neural networkT2-weightedCancer CenterPlanar acquisitionImaging sessionFat suppressionMR imagingSarcomaAnatomical orientationLGG-52. Volumetry-based response characterization of recurrent pediatric low-grade gliomas in PNOC clinical Neuro-oncology trials
von Reppert M, Lin M, Bousabarah K, Familiar A, Velasco R, Waanders A, Vossough A, Haddock A, Nicolaides T, Swanson K, Kazerooni A, Kline C, Nabavizadeh A, Haas-Kogan D, Prados M, Rubin J, Mueller S, Aboian M. LGG-52. Volumetry-based response characterization of recurrent pediatric low-grade gliomas in PNOC clinical Neuro-oncology trials. Neuro-Oncology 2022, 24: i100-i100. PMCID: PMC9165161, DOI: 10.1093/neuonc/noac079.364.Peer-Reviewed Original ResearchPediatric low-grade gliomasClinical trialsLow-grade gliomasRANO criteriaResponse assessmentNeuro-oncology trialsSingle-agent everolimusTreatment response analysisCentral imaging reviewInter-reader agreementClinical outcomesTumor sizeImaging reviewCystic componentTreatment responseTumor volumeTrue tumor volumeNovel treatmentsVolumetric assessmentTrial outcomesVolumetric measuresEntire tumorOverall discordanceNeuroradiology practiceTrialsOptimization of the BCLC Staging System for Locoregional Therapy for Hepatocellular Carcinoma by Using Quantitative Tumor Burden Imaging Biomarkers at MRI.
Borde T, Nezami N, Laage Gaupp F, Savic LJ, Taddei T, Jaffe A, Strazzabosco M, Lin M, Duran R, Georgiades C, Hong K, Chapiro J. Optimization of the BCLC Staging System for Locoregional Therapy for Hepatocellular Carcinoma by Using Quantitative Tumor Burden Imaging Biomarkers at MRI. Radiology 2022, 304: 228-237. PMID: 35412368, PMCID: PMC9270683, DOI: 10.1148/radiol.212426.Peer-Reviewed Original ResearchConceptsMedian overall survivalAdvanced-stage hepatocellular carcinomaTransarterial chemoembolizationHepatocellular carcinomaBCLC BBCLC COverall survivalTumor burdenBarcelona Clinic Liver Cancer (BCLC) staging systemLiver Cancer staging systemCancer (AJCC) staging systemConventional transarterial chemoembolizationDrug-eluting beadsAllocation of patientsContrast-enhanced MRIBackground PatientsSurvival benefitRetrospective studyStaging systemC tumorsTumor volumePatientsHeterogeneous patientsMonthsChemoembolization
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply